Catalyst Watch – Vol. 1, Edition 3 (10/2/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

October 1- EOD

It was a fairly busy day today in biotech land the sentiment certainly appears more positive. They participated in the market rally even though most were not big losers in.

Week’s Option Activity (9/23~9/27)

The following stocks had notable activity in their options during the past week(s): $EDAP (9/23): Bullish long term Call buys. 750 FEB14 2.50 strike Calls (stock at $2.68) were bought.

September 30-EOD

There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see.

September 30-EOD

There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see.

September 30-EOD

There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see.

ISIS Huntington’s Disease Program: A good start on an ambitious target

Huntington’s Disease (HD) is a neurodegenerative disease characterized by motor, cognitive and psychiatric symptoms. The most typical symptom, but by far not the only, is the occurrence of incontrollable, random.

Quick comments on Achillion and TG Therapeutics

(with Jason Chew) In biotech, all too often are investors given news on Friday that is not so good. With many updates expected by the end of the quarter, someone.

September 27- EOD

Not a particularly news rich day but the sector seemed to continue its momentum from yesterday and seemed to outperform the general market with a lot of green on a.

September 26-EOD

It was an interesting news day and biotechs even participated in the market strength today, which has not happened in a little while. I would not call the biotech action.

Catalyst Watch – Vol. 1, Edition 2 (9/26/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

What to look for at AASLD 2013

We wanted to take a moment to highlight some of the presentations at the 2013 Annual Meeting of the American Association for the Study of Liver Diseases. This conference takes.

September 25- EOD

A very interesting and odd day in the market today. Overall the market continued its weakness and biotechs were generally down. The market came back and it seemed to turn.

What to look for at ESMO 2013

Apropos to our post yesterday on upcoming medical conferences, we wanted to begin with some coverage of the European Cancer Congress 2013 (ECCO-ESMO). This conference takes place Friday, September 27th.

KaloBios: a look at KB003 and KB004

(jointly with Jason Chew) KaloBios (NASDAQ: KBIO) completed its initial public offering this past January, securing $61.5 million in proceeds to fund operations and it recently raised $30M in a.

September 24- EOD

Not a lot going on today, which works out well as it has been a busy day for me outside of biotech. The market seemed to find its footing a.

September 24- EOD

Not a lot going on today, which works out well as it has been a busy day for me outside of biotech. The market seemed to find its footing a.

September 24- EOD

Not a lot going on today, which works out well as it has been a busy day for me outside of biotech. The market seemed to find its footing a.

ACHN – In Consolidation Mode

Achillion Pharmaceuticals, Inc. (ACHN – Nasdaq) On  July 1, 2013 the FDA placed a clinical hold on Achillion’s hep C drug and the shares plunged 22% from $8.36 to $6.17 the.

Week’s Option Activity (9/16~9/20)

The following stocks had notable activity in their options during the past week: $GERN (9/17): 5,000 OCT 2.00 strike Puts (stock at $2.26) were purchased for 0.14 or $70,000. This.

Browsing 20 / 3 articles